Recent advances in chemotherapy for head and neck cancers

Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Uma C Sambargi [verfasserIn] D R Mahesh [verfasserIn] Anuradha Pai [verfasserIn] Prathima Maligi [verfasserIn] B K Ramanarayan [verfasserIn] C J Sanjay [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2012

Schlagwörter:	Head and neck cancers, chemotherapy, concomitant and induction chemotherapy

Übergeordnetes Werk:	In: Journal of Orofacial Sciences - Wolters Kluwer Medknow Publications, 2010, 4(2012), 1, Seite 15-19
Übergeordnetes Werk:	volume:4 ; year:2012 ; number:1 ; pages:15-19

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.4103/0975-8844.99880

Katalog-ID:	DOAJ009418431

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ009418431
003	DE-627
005	20230502080125.0
007	cr uuu---uuuuu
008	230225s2012 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.4103/0975-8844.99880 \|2 doi
035			\|a (DE-627)DOAJ009418431
035			\|a (DE-599)DOAJb3d782e78cd74773a16ddfcb94fc2546
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RK1-715
100	0		\|a Uma C Sambargi \|e verfasserin \|4 aut
245	1	0	\|a Recent advances in chemotherapy for head and neck cancers
264		1	\|c 2012
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers.
650		4	\|a Head and neck cancers, chemotherapy, concomitant and induction chemotherapy
653		0	\|a Dentistry
700	0		\|a D R Mahesh \|e verfasserin \|4 aut
700	0		\|a Anuradha Pai \|e verfasserin \|4 aut
700	0		\|a Prathima Maligi \|e verfasserin \|4 aut
700	0		\|a B K Ramanarayan \|e verfasserin \|4 aut
700	0		\|a C J Sanjay \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Orofacial Sciences \|d Wolters Kluwer Medknow Publications, 2010 \|g 4(2012), 1, Seite 15-19 \|w (DE-627)640573576 \|w (DE-600)2582357-7 \|x 23204737 \|7 nnns
773	1	8	\|g volume:4 \|g year:2012 \|g number:1 \|g pages:15-19
856	4	0	\|u https://doi.org/10.4103/0975-8844.99880 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/b3d782e78cd74773a16ddfcb94fc2546 \|z kostenfrei
856	4	0	\|u http://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=15;epage=19;aulast=Sambargi \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0975-8844 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2012 \|e 1 \|h 15-19

Indexfelder

author_variant	u c s ucs d r m drm a p ap p m pm b k r bkr c j s cjs
matchkey_str	article:23204737:2012----::eetdacsnhmteayohaa
hierarchy_sort_str	2012
callnumber-subject-code	RK
publishDate	2012
allfields	10.4103/0975-8844.99880 doi (DE-627)DOAJ009418431 (DE-599)DOAJb3d782e78cd74773a16ddfcb94fc2546 DE-627 ger DE-627 rakwb eng RK1-715 Uma C Sambargi verfasserin aut Recent advances in chemotherapy for head and neck cancers 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers. Head and neck cancers, chemotherapy, concomitant and induction chemotherapy Dentistry D R Mahesh verfasserin aut Anuradha Pai verfasserin aut Prathima Maligi verfasserin aut B K Ramanarayan verfasserin aut C J Sanjay verfasserin aut In Journal of Orofacial Sciences Wolters Kluwer Medknow Publications, 2010 4(2012), 1, Seite 15-19 (DE-627)640573576 (DE-600)2582357-7 23204737 nnns volume:4 year:2012 number:1 pages:15-19 https://doi.org/10.4103/0975-8844.99880 kostenfrei https://doaj.org/article/b3d782e78cd74773a16ddfcb94fc2546 kostenfrei http://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=15;epage=19;aulast=Sambargi kostenfrei https://doaj.org/toc/0975-8844 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2012 1 15-19
spelling	10.4103/0975-8844.99880 doi (DE-627)DOAJ009418431 (DE-599)DOAJb3d782e78cd74773a16ddfcb94fc2546 DE-627 ger DE-627 rakwb eng RK1-715 Uma C Sambargi verfasserin aut Recent advances in chemotherapy for head and neck cancers 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers. Head and neck cancers, chemotherapy, concomitant and induction chemotherapy Dentistry D R Mahesh verfasserin aut Anuradha Pai verfasserin aut Prathima Maligi verfasserin aut B K Ramanarayan verfasserin aut C J Sanjay verfasserin aut In Journal of Orofacial Sciences Wolters Kluwer Medknow Publications, 2010 4(2012), 1, Seite 15-19 (DE-627)640573576 (DE-600)2582357-7 23204737 nnns volume:4 year:2012 number:1 pages:15-19 https://doi.org/10.4103/0975-8844.99880 kostenfrei https://doaj.org/article/b3d782e78cd74773a16ddfcb94fc2546 kostenfrei http://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=15;epage=19;aulast=Sambargi kostenfrei https://doaj.org/toc/0975-8844 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2012 1 15-19
allfields_unstemmed	10.4103/0975-8844.99880 doi (DE-627)DOAJ009418431 (DE-599)DOAJb3d782e78cd74773a16ddfcb94fc2546 DE-627 ger DE-627 rakwb eng RK1-715 Uma C Sambargi verfasserin aut Recent advances in chemotherapy for head and neck cancers 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers. Head and neck cancers, chemotherapy, concomitant and induction chemotherapy Dentistry D R Mahesh verfasserin aut Anuradha Pai verfasserin aut Prathima Maligi verfasserin aut B K Ramanarayan verfasserin aut C J Sanjay verfasserin aut In Journal of Orofacial Sciences Wolters Kluwer Medknow Publications, 2010 4(2012), 1, Seite 15-19 (DE-627)640573576 (DE-600)2582357-7 23204737 nnns volume:4 year:2012 number:1 pages:15-19 https://doi.org/10.4103/0975-8844.99880 kostenfrei https://doaj.org/article/b3d782e78cd74773a16ddfcb94fc2546 kostenfrei http://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=15;epage=19;aulast=Sambargi kostenfrei https://doaj.org/toc/0975-8844 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2012 1 15-19
allfieldsGer	10.4103/0975-8844.99880 doi (DE-627)DOAJ009418431 (DE-599)DOAJb3d782e78cd74773a16ddfcb94fc2546 DE-627 ger DE-627 rakwb eng RK1-715 Uma C Sambargi verfasserin aut Recent advances in chemotherapy for head and neck cancers 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers. Head and neck cancers, chemotherapy, concomitant and induction chemotherapy Dentistry D R Mahesh verfasserin aut Anuradha Pai verfasserin aut Prathima Maligi verfasserin aut B K Ramanarayan verfasserin aut C J Sanjay verfasserin aut In Journal of Orofacial Sciences Wolters Kluwer Medknow Publications, 2010 4(2012), 1, Seite 15-19 (DE-627)640573576 (DE-600)2582357-7 23204737 nnns volume:4 year:2012 number:1 pages:15-19 https://doi.org/10.4103/0975-8844.99880 kostenfrei https://doaj.org/article/b3d782e78cd74773a16ddfcb94fc2546 kostenfrei http://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=15;epage=19;aulast=Sambargi kostenfrei https://doaj.org/toc/0975-8844 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2012 1 15-19
allfieldsSound	10.4103/0975-8844.99880 doi (DE-627)DOAJ009418431 (DE-599)DOAJb3d782e78cd74773a16ddfcb94fc2546 DE-627 ger DE-627 rakwb eng RK1-715 Uma C Sambargi verfasserin aut Recent advances in chemotherapy for head and neck cancers 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers. Head and neck cancers, chemotherapy, concomitant and induction chemotherapy Dentistry D R Mahesh verfasserin aut Anuradha Pai verfasserin aut Prathima Maligi verfasserin aut B K Ramanarayan verfasserin aut C J Sanjay verfasserin aut In Journal of Orofacial Sciences Wolters Kluwer Medknow Publications, 2010 4(2012), 1, Seite 15-19 (DE-627)640573576 (DE-600)2582357-7 23204737 nnns volume:4 year:2012 number:1 pages:15-19 https://doi.org/10.4103/0975-8844.99880 kostenfrei https://doaj.org/article/b3d782e78cd74773a16ddfcb94fc2546 kostenfrei http://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=15;epage=19;aulast=Sambargi kostenfrei https://doaj.org/toc/0975-8844 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2012 1 15-19
language	English
source	In Journal of Orofacial Sciences 4(2012), 1, Seite 15-19 volume:4 year:2012 number:1 pages:15-19
sourceStr	In Journal of Orofacial Sciences 4(2012), 1, Seite 15-19 volume:4 year:2012 number:1 pages:15-19
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Head and neck cancers, chemotherapy, concomitant and induction chemotherapy Dentistry
isfreeaccess_bool	true
container_title	Journal of Orofacial Sciences
authorswithroles_txt_mv	Uma C Sambargi @@aut@@ D R Mahesh @@aut@@ Anuradha Pai @@aut@@ Prathima Maligi @@aut@@ B K Ramanarayan @@aut@@ C J Sanjay @@aut@@
publishDateDaySort_date	2012-01-01T00:00:00Z
hierarchy_top_id	640573576
id	DOAJ009418431
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ009418431</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502080125.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4103/0975-8844.99880</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ009418431</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJb3d782e78cd74773a16ddfcb94fc2546</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RK1-715</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Uma C Sambargi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recent advances in chemotherapy for head and neck cancers</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Head and neck cancers, chemotherapy, concomitant and induction chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dentistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D R Mahesh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anuradha Pai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Prathima Maligi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">B K Ramanarayan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">C J Sanjay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Orofacial Sciences</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2010</subfield><subfield code="g">4(2012), 1, Seite 15-19</subfield><subfield code="w">(DE-627)640573576</subfield><subfield code="w">(DE-600)2582357-7</subfield><subfield code="x">23204737</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:15-19</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4103/0975-8844.99880</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/b3d782e78cd74773a16ddfcb94fc2546</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=15;epage=19;aulast=Sambargi</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0975-8844</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2012</subfield><subfield code="e">1</subfield><subfield code="h">15-19</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Uma C Sambargi
spellingShingle	Uma C Sambargi misc RK1-715 misc Head and neck cancers, chemotherapy, concomitant and induction chemotherapy misc Dentistry Recent advances in chemotherapy for head and neck cancers
authorStr	Uma C Sambargi
ppnlink_with_tag_str_mv	@@773@@(DE-627)640573576
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RK1-715
illustrated	Not Illustrated
issn	23204737
topic_title	RK1-715 Recent advances in chemotherapy for head and neck cancers Head and neck cancers, chemotherapy, concomitant and induction chemotherapy
topic	misc RK1-715 misc Head and neck cancers, chemotherapy, concomitant and induction chemotherapy misc Dentistry
topic_unstemmed	misc RK1-715 misc Head and neck cancers, chemotherapy, concomitant and induction chemotherapy misc Dentistry
topic_browse	misc RK1-715 misc Head and neck cancers, chemotherapy, concomitant and induction chemotherapy misc Dentistry
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Orofacial Sciences
hierarchy_parent_id	640573576
hierarchy_top_title	Journal of Orofacial Sciences
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)640573576 (DE-600)2582357-7
title	Recent advances in chemotherapy for head and neck cancers
ctrlnum	(DE-627)DOAJ009418431 (DE-599)DOAJb3d782e78cd74773a16ddfcb94fc2546
title_full	Recent advances in chemotherapy for head and neck cancers
author_sort	Uma C Sambargi
journal	Journal of Orofacial Sciences
journalStr	Journal of Orofacial Sciences
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2012
contenttype_str_mv	txt
container_start_page	15
author_browse	Uma C Sambargi D R Mahesh Anuradha Pai Prathima Maligi B K Ramanarayan C J Sanjay
container_volume	4
class	RK1-715
format_se	Elektronische Aufsätze
author-letter	Uma C Sambargi
doi_str_mv	10.4103/0975-8844.99880
author2-role	verfasserin
title_sort	recent advances in chemotherapy for head and neck cancers
callnumber	RK1-715
title_auth	Recent advances in chemotherapy for head and neck cancers
abstract	Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers.
abstractGer	Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers.
abstract_unstemmed	Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Recent advances in chemotherapy for head and neck cancers
url	https://doi.org/10.4103/0975-8844.99880 https://doaj.org/article/b3d782e78cd74773a16ddfcb94fc2546 http://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=15;epage=19;aulast=Sambargi https://doaj.org/toc/0975-8844
remote_bool	true
author2	D R Mahesh Anuradha Pai Prathima Maligi B K Ramanarayan C J Sanjay
author2Str	D R Mahesh Anuradha Pai Prathima Maligi B K Ramanarayan C J Sanjay
ppnlink	640573576
callnumber-subject	RK - Dentistry
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.4103/0975-8844.99880
callnumber-a	RK1-715
up_date	2024-07-03T23:33:43.082Z
_version_	1803602753573879808
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ009418431</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502080125.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4103/0975-8844.99880</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ009418431</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJb3d782e78cd74773a16ddfcb94fc2546</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RK1-715</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Uma C Sambargi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recent advances in chemotherapy for head and neck cancers</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Systemic chemotherapy is increasingly being used with radiotherapy for the radical treatment of advanced head and neck cancers. Chemotherapy offers modest benefits in the metastatic setting. Platinum containing agents are the most active drugs and form the mainstay of most chemotherapy schedules. In recent years taxanes have shown activity in head and neck cancers and are being -incorporated into neo-adjuvant and concomitant chemotherapy regimens. Targeted agents and epidermal growth factor receptor (EGFR) inhibitors, like cetuximab, in particular, have shown benefit in the metastatic and the concomitant setting. EGFR inhibitors and other targeted agents form the thrust of pre-clinical and clinical research into the systemic treatment of head and neck cancers.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Head and neck cancers, chemotherapy, concomitant and induction chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dentistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D R Mahesh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anuradha Pai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Prathima Maligi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">B K Ramanarayan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">C J Sanjay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Orofacial Sciences</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2010</subfield><subfield code="g">4(2012), 1, Seite 15-19</subfield><subfield code="w">(DE-627)640573576</subfield><subfield code="w">(DE-600)2582357-7</subfield><subfield code="x">23204737</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:15-19</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4103/0975-8844.99880</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/b3d782e78cd74773a16ddfcb94fc2546</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=15;epage=19;aulast=Sambargi</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0975-8844</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2012</subfield><subfield code="e">1</subfield><subfield code="h">15-19</subfield></datafield></record></collection>
score	7.4017506

Nicht das Richtige dabei?

Schreiben Sie uns!

Recent advances in chemotherapy for head and neck cancers

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?